VABYSMO
Vabysmo (faricimab-svoa) is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor. It is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. This therapeutic agent is used to manage retinal conditions where vascular instability and increased permeability are present.
How VABYSMO Works
Faricimab is a humanized bispecific antibody that functions by binding to and inhibiting both VEGF-A and Ang-2. By blocking VEGF-A, the drug suppresses the proliferation of endothelial cells, the formation of new blood vessels, and vascular leakage. Inhibition of Ang-2 is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. These dual pathways address the increased levels of Ang-2 found in patients with certain macular and retinal vascular diseases.
Details
- Status
- Prescription
- First Approved
- 2022-01-28
- Routes
- INTRAVITREAL
- Dosage Forms
- INJECTABLE
VABYSMO Approval History
What VABYSMO Treats
3 indicationsVABYSMO is approved for 3 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Neovascular Age-Related Macular Degeneration
- Diabetic Macular Edema
- Macular Edema Following Retinal Vein Occlusion
VABYSMO Target & Pathway
ProTarget
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
Pathway Context
VEGF binds to VEGFR on blood vessel cells to stimulate new vessel formation
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
VABYSMO Competitors
Pro6 other drugs also target VEGF. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (VEGF). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to VABYSMO
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VABYSMO FDA Label Details
ProIndications & Usage
FDA Label (PDF)VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with: VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Diabetic Macular Edema (DME) Macular Edema Following Retinal Vein Occlusion (RVO) 1.1 Neovascular (wet) Age-Related Macular Degeneration (nAMD) 1.2 Diabetic Macular Edema (DME) 1.3 Macular Edema Following Retinal Vein Occlusion (RVO)
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.